



For Immediate Release

## United Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left Behind—Ever

Report available at [corporateresponsibility.unither.com](https://corporateresponsibility.unither.com)

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., September 10, 2024 – United Therapeutics Corporation (Nasdaq: **UTHR**), a public benefit corporation (**PBC**), today announced the release of its 2024 Corporate Responsibility and Public Benefit Report (**Report**) covering its FY 2023 progress toward its public benefit goals and objectives and summarizing its efforts to advance the interests of patients and other stakeholders.

“Our 2023 financial performance helps set us up for the next revolutionary wave of growth ahead—our organ manufacturing work, which you will read more about in this Report,” said **Christopher Causey**, Chair of the Nominating and Governance Committee of the United Therapeutics Board of Directors. “Still, we have seen the research demonstrating the connections between patient health and ecosystem health, which is why we maintain our site net zero energy goal for all new construction, where feasible, and invest in groundbreaking green building efforts like our *Phase Five* LEED Gold certified warehouse in North Carolina. One of the things that I so value about this company is our commitment to walk the talk.”

As a PBC, United Therapeutics is obligated to report its progress toward its public benefit purpose—to *provide a brighter future for patients through the development of novel pharmaceutical therapies, and technologies that expand the availability of transplantable organs*. It pursues this purpose alongside its obligations to balance the interests of its other stakeholders, including employees, shareholders, the environment, and the local communities in which it operates.

United Therapeutics aligns its environmental, social, and governance (**ESG**) priorities and performance with its PBC goals. The following are some highlights from this year’s Report:

- The company served more than **14,500** patients, including more than 100 benefiting from its centralized *ex vivo* lung perfusion (**EVL**P) service in 2023, and more than 400 since service launch;
- Its patient assistance program has enabled more than **32,000 patients** secure access to treatments since 2010;
- More than **90 percent** of its employees agree, year-after-year since 2018, that United Therapeutics is a **Great Place to Work**;
- With the LEED Gold certification of its *Phase Five* Warehouse, approximately **26% of United Therapeutics’ properties are LEED certified**, including its LEED Platinum site net zero commercial building called the *Unisphere*;
- United Therapeutics remains a steadfast contributor to, and consumer of, renewable power through the **7-MW capacity onsite solar fields** it maintains on its properties.

“Patient needs drive everything we do at UT,” said **James Edgemond**, Chief Financial Officer and Treasurer of United Therapeutics. “As Chris notes, we believe in the links across issues, which is why our PBC goals align with our patients, our people, and our planet. We manage the balance across our resources—human, financial, and environmental—to achieve better, long-lasting outcomes.”

Alongside the publication of this Report, United Therapeutics also announced the launch of its updated corporate responsibility website. This site includes two new sections: [Reports and Other Resources](#), which links to documents of interest to stakeholders including topic overviews, policies, and more, and [Impact Stories](#), which showcases the creative spark indicative of UT employees.

Find the full report at [corporateresponsibility.unither.com](https://corporateresponsibility.unither.com).

## United Therapeutics: Enabling Inspiration

At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun; we do good. We are the first publicly traded biotech or pharmaceutical company to take the form of a public benefit corporation. Our public benefit purpose is to *provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.*

You can learn more about what it means to be a PBC here: [unither.com/PBC](https://unither.com/PBC).

## Forward-looking Statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding progress toward achieving our public benefit purpose and furthering the interests of other stakeholders (including employees, shareholders, the environment, and local communities in which we operate): our progress toward a future where no patient gets left behind; our next revolutionary wave of growth ahead—our organ manufacturing work; our efforts to steward our resources – human, financial, and environmental – to get better, long-lasting outcomes; our net zero energy goal for all new construction, where feasible; our commitment to taking meaningful, evidence-based actions; and our goals of innovating for the unmet medical needs of our patients and to benefit our other stakeholders and furthering our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of September 10, 2024, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason.

### For Further Information Contact:

Catherine Sheehy at (240) 398-3504 (sustainability)

Dewey Steadman at (202) 919-4097 (investors/media)

<https://ir.unither.com/contact-uthr/>

Source: United Therapeutics Corporation